Profile
Graeme Meintjes is a Clinical Professor of Infectious Diseases at Queen Mary University of London (QMUL) and a Professor of Medicine at the University of Cape Town (UCT). He is an adult Infectious Diseases Specialist. He leads a research programme that focuses on the clinical conditions affecting patients with advanced HIV disease including disseminated HIV-associated tuberculosis, the immune reconstitution inflammatory syndrome and cryptococcal meningitis. His group also investigates drug-resistant tuberculosis, diagnostics for TB and antiretroviral therapy strategies. He has been the PI or local PI of several clinical trials and conducts observational cohort studies that address questions related to disease pathogenesis.
Research
Research Interests:
Graeme Meintjes’ research programme is focused on tuberculosis and other conditions that affect patients with advanced HIV disease. He is currently Chair of the Trial Steering Committee of the REVIVE trial investigating azithromycin enhanced prophylaxis for adults with advanced HIV disease starting or restarting antiretroviral therapy in Africa. He is co-PI of the NEW STRAT-TB trial investigating novel strategies for the management of patients admitted to hospital with HIV-associated TB. He is national PI in South Africa of the EFFECT trial which investigates fluconazole plus flucytosine for the treatment of cryptococcal antigenaemia in people with HIV. His research group has made contributions to the understanding of the tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS), the use of new and repurposed drugs for treating drug-resistant TB, urine diagnostics for tuberculosis, the treatment of cryptococcal meningitis and antiretroviral therapy strategies for treating HIV in programmatic settings. His group conducts clinical trials, observational cohort studies and translational studies of pathogenesis and collaborates on TB and HIV pharmacokinetic studies.
Publications
Key Publications
Meintjes G, Maartens G. HIV-Associated Tuberculosis. N Engl J Med. 2024 Jul 25;391(4):343-355. doi: 10.1056/NEJMra2308181.
Schutz C, Barr D, Andrade BB, Shey M, Ward A, Janssen S, Burton R, Wilkinson KA, Sossen B, Fukutani KF, Nicol M, Maartens G, Wilkinson RJ, Meintjes G. Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study. PLoS Med. 2019 Jul 5;16(7):e1002840. doi: 10.1371/journal.pmed.1002840.
Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson RJ, Lynen L; PredART Trial Team. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med. 2018 Nov 15;379(20):1915-1925. doi: 10.1056/NEJMoa1800762.
Zhao Y, Griesel R, Omar Z, Simmons B, Hill A, van Zyl G, Keene C, Maartens G, Meintjes G. Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial. Clin Infect Dis. 2023 May 24;76(10):1832-1840. doi: 10.1093/cid/ciad023.
Brust JCM, Gandhi NR, Wasserman S, Maartens G, Omar SV, Ismail NA, Campbell A, Joseph L, Hahn A, Allana S, Hernandez-Romieu AC, Zhang C, Mlisana K, Viljoen CA, Zalta B, Ebrahim I, Franczek M, Master I, Ramangoaela L, Te Riele J, Meintjes G. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study. Clin Infect Dis. 2021 Dec 6;73(11):2083-2092. doi: 10.1093/cid/ciab335.
All Publications
